Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.46 |
| ▸ | TUBB | P07437 | 1/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7234204 | 0.95 | LMNA (0.70) | LMNAKDM4ESMN1; SMN2CYP1A2KCNH2 | |
| SCHEMBL7227411 | 0.93 | LMNA (0.74) | LMNAKDM4ESMN1; SMN2CYP1A2KCNH2 | |
| SCHEMBL7764919 | 0.93 | LMNA (0.74) | LMNAKDM4ESMN1; SMN2CYP1A2KCNH2 | |
| SCHEMBL7224626 | 0.88 | LMNA (0.74) | LMNAKDM4ESMN1; SMN2CYP1A2KCNH2 | |
| SCHEMBL7763545 | 0.88 | LMNA (0.74) | LMNAKDM4ESMN1; SMN2CYP1A2KCNH2 | |
| SCHEMBL7225205 | 0.88 | LMNA (0.79) | LMNAKDM4ESMN1; SMN2CYP1A2KCNH2 | |
| Nadifloxacin SCHEMBL28112583 | 0.84 | LMNA (0.93) | LMNAKDM4ESMN1; SMN2CYP1A2KCNH2 | |
| Levonadifloxacin SCHEMBL36594 | 0.84 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2KCNH2 | |
| Nadifloxacin SCHEMBL3818938 | 0.84 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2KCNH2 | |
| Levonadifloxacin SCHEMBL29390463 | 0.84 | LMNA (1.00) | LMNAKDM4ESMN1; SMN2CYP1A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608078-B2 | Gramnegative bacteria | WOCKHARDT LIMITED (IN) | 2003-08-19 | — | — | US | claimed |
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | WOCKHARDT RESEARCH CENTER | 2002-11-07 | — | — | US | claimed |
| US-6608078-B2 | Gramnegative bacteria | WOCKHARDT LIMITED (IN) | 2003-08-19 | — | — | US | disclosed |
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | WOCKHARDT RESEARCH CENTER | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | ALPI, POLR1C, POLI | LMNA 1788/4885KDM4E 2308/4885SMN1; SMN2 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.